DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-863/S-019

Otsuka America Pharmaceuticals, Inc.
Attention: Mr. Edwin O. Billips
2440 Research Blvd.
Rockville, MD 20850

Dear Mr. Billips:

We refer to your supplemental new drug application submitted on October 11, 2005, received October 13, 2005, under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Pletal (cilostazol) 50 mg and 100 mg Tablets. We also refer to our approvable letter dated August 10, 2006 and your Class 1 resubmission dated November 29, 2006.

We also acknowledge receipt of your submission dated December 8, 2006.

We note the following postmarketing study commitments, listed in our January 15, 1999 approval letter:

> Study Commitment 1: A single-center, randomized, three-period cross-over, single-dose study of the effects of ketoconazole or grapefruit juice on cilostazol (OPC-13013) pharmacokinetics.
>
> Study Commitment 2: A study to understand better the risk, if any, of long-term use of cilostazol. This trial will compare the effects of cilostazol with those of pentoxifylline and placebo in about 1800 intermittent claudication patients of any severity (including patients on clopidogrel). Efficacy will be monitored for a total of 12 months.

The final study report for Study Commitment 1, submitted on May 16, 2001, fulfilled this commitment as stated in the letter approving labeling supplement 007 signed on February 4, 2004.

The study you designed to meet Study Commitment 2 was entitled, "A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Parallel-Arm Study to Assess the Long Term Effects of Pletal (Cilostazol) versus Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease" known as the CASTLE Study.

We have reviewed your submissions and conclude that the above commitments are now fulfilled. This completes all of your postmarketing study commitments acknowledged in our January 15, 1999 approval 1etter.

We have also completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the submitted final printed labeling to the package insert submitted November 29, 2006.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for this application.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call:

Ms. Meg Pease-Fye, M.S.
Regulatory Health Project Manager
(301) 796-1130

Sincerely,

{See appended electronic signature page}

Norman Stockbridge, M.D., Ph.D.
Director
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure : approved labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Norman Stockbridge

1/18/2007 08:51:11 AM